Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

Eleven forms of cancer are becoming increasingly common among young people in England. Experts at the Institute of Cancer Research and Imperial College London stressed that cancer among younger people is still rare, and that everyone can reduce their risk by simply switching to a healthier lifestyle. However, why tumours have started to develop in people in their late teens, or in their 20s, 30s and 40s, remains unclear. The study further shows that the reasons behind rising cancer cases are elusive. However, this research does indicate a decade-long pattern of people becoming overweight.

Why does one develop cancer?

A team of scientists worked towards understanding why a person develops cancer. They examined national trends in lifestyle and cancer to identify patterns. Researchers found that cases of the following types of cancer were rising:

1. Liver
2. Kidney
3. Thyroid
4. Bowel
5. Multiple myeloma
6. Womb lining
7. Mouth
8. Ovarian
9. Breast
10. Gallbladder
11. Pancreatic

Researchers found that breast and bowel cancers are common among younger adults, with 11,500 cases in a year, while gallbladder and pancreatic cancers were much rarer. It was also noted that ovarian and bowel cancers were exclusively being reported in young people, whereas the other nine were increasing in adults as well. The study by the Institute of Cancer Research and Imperial College London also analysed behavioural patterns known to raise cancer risk.

Researchers also found patterns related to alcohol intake, smoking levels, red and processed meat consumption, and diets low in fibre. These factors play a role in cancer development, but do not conclusively explain why cancer rates are increasing. Century-old tumour patterns, however, may explain why younger people are getting bowel cancer.

How to check for bowel cancer risk?

The report suggested that the only factors that align with an increased risk of cancer are obesity and being overweight, both of which have been on the rise since the 1990s. Extra fat tissue can alter hormones such as insulin, which can increase cancer risk. For instance, in the case of bowel cancer, for every 100 extra cases, 20 could be attributed to excess weight, while 80 remain unexplained. Researchers also note that it is important to prevent all cancers, not just the additional cases. It is estimated that nearly 40 per cent of cancers worldwide can be prevented through appropriate lifestyle choices, such as quitting smoking.

How to reduce cancer risk?

Quitting smoking and avoiding alcohol are among the simplest and most well-known ways of reducing cancer risk. However, experts say that other measures can also help. Maintaining a healthy body weight and staying physically active are simple ways to reduce cancer risk. Researchers also emphasise that while cancer rates are rising among younger people, the risk of tumours remains significantly higher in older age groups.

Researchers found that one in 1,000 people aged 20, 30 and 40 are diagnosed with cancer every year, compared to one in 100 among older age groups aged 50, 60 and 70. The search for other risk factors continues. Inflammation, sweetened drinks, gut bacteria, and air pollution must be addressed in time to reduce cancer risk. It is also being investigated whether improvements in cancer detection are contributing to earlier diagnoses in younger individuals.

The study’s findings are published in the BMJ Oncology.

Cervical cancer is a slow-developing cancer that occurs in the lower part of the uterus. It is caused by a persistent HPV infection, which usually occurs in women in their prime. Some of the symptoms of cervical cancer include pelvic pain and abnormal bleeding. Experts say that timely detection through a Pap smear or prevention with an HPV vaccine can make a difference. However, according to a study published in The Lancet, high-income countries are on the right track to eliminate cervical cancer.

What causes cervical cancer?

The study published in The Lancet notes that high-income countries are on the right track towards cervical cancer prevention through vaccination and screening. By 2048, low- and middle-income countries will see only slight reductions over the next century. As a result, the gap between regions will likely widen dramatically. Experts have found that 99 per cent of cervical cancer cases are linked to infection with human papillomaviruses (HPV), a virus that is transmitted through sexual contact.

Preventing cervical cancer

Cervical cancer, according to experts, can be prevented through the HPV vaccine and regular screenings. The elimination target set by the World Health Organization is fewer than four cases per one lakh women. Every country, as per the WHO, must meet the ‘90-70-90’ targets by 2030. This means 90 per cent HPV vaccine coverage among girls by the age of 15, 70 per cent of women screened between the ages of 35 and 45, and 90 per cent of women with pre-cancer and cancer treated. This would be considered being on track for cervical cancer elimination in the coming century.

Researchers note that reaching the WHO targets for screening and vaccination, for HPV elimination, or for introducing universal vaccination with high coverage, is essential for the elimination of cervical cancer. This could help bridge global inequalities in disease management. Achieving the 90-70-90 goal can avert 37 million cancer cases by the next century, thereby accelerating progress in eliminating the disease. The model, however, suggests that most countries are unlikely to reach the target without increasing investments in this direction.

The research model

Researchers proposed five HPV-centric prevention strategies. Under a status quo model, cervical cancer incidence could decline by 23 per cent, consequently leading to inequalities in disease management. Experts found that achieving 90 per cent vaccination coverage in low- and middle-income countries would reduce inequalities and help eliminate cancer. Research authors also noted that recent advancements, such as single-dose vaccines at a lower cost, could accelerate cervical cancer elimination worldwide.

Global efforts from international agencies and governments are also important. A September 2022 study published in The Lancet Oncology found that a single-dose cervical cancer vaccine with lasting protection and 90 per cent coverage could prevent 78 per cent of cancer cases in India.

After a long day at work, the occasional glass of wine helps many people unwind. However, some struggle to strike a balance and get involved in binge drinking habits. If you are someone who is unable to give up that frequent dose of cocktails, then a study claims that weight loss drugs can come to your rescue. Experts have found that alcoholics who are obese, when given Wegovy, could curb their drinking habits by as much as 70 per cent. A study in Denmark was led by experts from the Mental Health Centre Copenhagen and Frederiksberg Hospital, and experts used semaglutide on 108 obese patients seeking treatment for alcohol use disorder.

Can weight loss drugs help curb drinking habits?

Half the participants in the study were given 2.4 mg of the drug for six months. The other half were also given a dummy drug. Researchers found that people who were on weight loss drugs had fewer days of binge drinking. Furthermore, their alcohol cravings also dipped compared to people on placebo. Before the trial began, participants engaged in binge drinking on an average of 17 days per month.

Researchers also noted that people who were given semaglutide for six months saw their binge drinking days reduce to five in a 30-day period. This correlated to a 40 per cent dip in drinking days in a month, compared to a 26 per cent dip in the placebo group. These dummy drugs helped reduce drinking days to nine. In terms of alcohol quantity, trial participants drank roughly 2,200 g in the 30 days before the trial started. This meant about 154 drinks in a month, or five per day. Over a period of six months after the trial, there was an impressive 70 per cent dip — from an average of 154 drinks a month to 46 drinks a month in people who were taking semaglutide.

What are the benefits of semaglutide?

Alcohol consumption dipped by an impressive 47 per cent in the dummy drug group as well. The study found that overall alcohol consumption can be reduced among semaglutide users compared to people who were taking the placebo. Researchers found that semaglutide not only affects appetite but also influences biological mechanisms associated with addiction.

Independent researchers found that the results were encouraging and strong enough to be used in helping people struggling with alcohol use problems. However, more research is required in this area. Researchers also noted that there were no follow-ups with the participants after the semaglutide treatment ended. This means that experts could not be fully certain whether people reverted to their old drinking habits once they stopped using the medicine.

What are the health benefits of weight loss drugs?

Apart from inducing weight loss, weight loss drugs have the following health benefits:

1. Quitting smoking
2. Can help kick drug habits such as cocaine use
3. Lower risk of heart attack or stroke
4. May help reduce blood pressure and cholesterol to improve heart health
5. Lower risk of dementia